EUVIMEDEUVIMED entdecken
Crossref

Simultaneously blocking ANGPTL3 and IL-1β for the treatment of atherosclerosis through lipid-lowering and anti-inflammation

Hanqi Wang, Xiaozhi Hu, Yuting Zhang, An Zhu, Jiajun Fan, Zhengyu Wu, Xuebin Wang, Wei Hu, Dianwen Ju

Inflammation Research · 2024

DOI: 10.1007/s00011-024-01941-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammation Research, 2024. Verfasst von Hanqi Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Minhang Hospital, Fudan University, No. 170 Zisong Road, Minhang District, Shanghai, China. Hauptthemen laut MEDLINE: Atherosclerosis, Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Recombinant Fusion Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Blood lipid levels play a critical role in the progression of atherosclerosis. However, even with adequate lipid reduction, significant residual cardiovascular risk remains. Therefore, it is necessary to seek novel therapeutic strategies for atherosclerosis that can not only lower lipid levels but also inhibit inflammation simultaneously. METHODS: The fusion protein FD03-IL-1Ra was designed by linking the Angiopoietin-like 3 (ANGPTL3) nanobody and human interleukin-1 receptor antagonist (IL-1Ra) sequences to a mutated human immunoglobulin gamma 1 (IgG1) Fc. This construct was transfected into HEK293 cells for expression. The purity and thermal stability of the fusion protein were assessed using SDS-PAGE, SEC-HPLC, and differential scanning calorimetry. Binding affinities of the fusion protein to ANGPTL3 and IL-1 receptor were measured using Biacore T200. The biological activity of the fusion protein was validated through in vitro experiments. The therapeutic efficacy of the fusion protein was evaluated in an ApoE-/- mouse model of atherosclerosis, including serum lipid level determination, histological analysis of aorta and aortic sinus sections, and detection of inflammatory and oxidative stress markers. ImageJ software was utilized for quantitative image analysis. Statistical analysis was performed using one-way ANOVA followed by Bonferroni post hoc test. RESULTS: The FD03-IL-1Ra fusion protein was successfully expressed, with no polymer formation detected, and it demonstrated good thermal and conformational stability. High affinity for both murine and human ANGPTL3 was exhibited by FD03-IL-1Ra, and it was able to antagonize hANGPTL3's inhibition of LPL activity. FD03-IL-1Ra also showed high affinity for both murine and human IL-1R, inhibiting IL-6 expression in A549 cells induced by IL-1β stimulation, as well as suppressing IL-1β-induced activity inhibition in A375.S2 cells. Our study revealed that the fusion protein effectively lowered serum lipid levels and alleviated inflammatory responses in mice. Furthermore, the fusion protein enhanced plaque stability by increasing collagen content within atherosclerotic plaques. CONCLUSIONS: These findings highlighted the potential of bifunctional interleukin-1 receptor antagonist and ANGPTL3 antibody fusion proteins for ameliorating the progression of atherosclerosis, presenting a promising novel therapeutic approach targeting both inflammation and lipid levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisAngiopoietin-like ProteinsAngiopoietin-Like Protein 3Recombinant Fusion ProteinsInterleukin-1betaAnimalsHumansHEK293 CellsMaleInterleukin 1 Receptor Antagonist ProteinMiceLipidsMice, Inbred C57BLAnti-Inflammatory AgentsAortaHypolipidemic AgentsSingle-Domain Antibodies

Stichwörter der Autor:innen

ANGPTL3AtherosclerosisFusion proteinIL-1Ra

Substanzen

Angiopoietin-like ProteinsAngiopoietin-Like Protein 3Recombinant Fusion ProteinsInterleukin-1betaInterleukin 1 Receptor Antagonist ProteinLipidsAngptl3 protein, mouseAnti-Inflammatory AgentsANGPTL3 protein, humanHypolipidemic Agents

Autor:innen und Institutionen

  • Department of Cardiology, Minhang Hospital, Fudan University, No. 170 Zisong Road, Minhang District, Shanghai, China.
  • Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, No. 826 Zhangheng Road, Pudong New District, Shanghai, China.
  • TAU Cambridge Ltd, The Bradfield Centre UNIT 184, Cambridge Science Park, Cambridge, CB4 0GA, UK.
  • Department of Pharmacy, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, 355 Luding Road, Putuo District, Shanghai, China. binxuewang@sjtu.edu.cn.
  • Department of Cardiology, Minhang Hospital, Fudan University, No. 170 Zisong Road, Minhang District, Shanghai, China. hu_wei@fudan.edu.cn.
  • Department of Cardiology, Minhang Hospital, Fudan University, No. 170 Zisong Road, Minhang District, Shanghai, China. dianwenju@fudan.edu.cn.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Wang, H., Hu, X., Zhang, Y., Zhu, A., Fan, J., Wu, Z., Wang, X., Hu, W., & Ju, D. (2024). Simultaneously blocking ANGPTL3 and IL-1β for the treatment of atherosclerosis through lipid-lowering and anti-inflammation. Inflammation Research. https://doi.org/10.1007/s00011-024-01941-1

Vancouver

Wang H, Hu X, Zhang Y, Zhu A, Fan J, Wu Z, et al. Simultaneously blocking ANGPTL3 and IL-1β for the treatment of atherosclerosis through lipid-lowering and anti-inflammation. Inflammation Research. 2024. doi:10.1007/s00011-024-01941-1

BibTeX
@article{Wang2024,
  author = {Wang, Hanqi and Hu, Xiaozhi and Zhang, Yuting and Zhu, An and Fan, Jiajun and Wu, Zhengyu and Wang, Xuebin and Hu, Wei and Ju, Dianwen},
  title = {Simultaneously blocking ANGPTL3 and IL-1β for the treatment of atherosclerosis through lipid-lowering and anti-inflammation},
  journal = {Inflammation Research},
  year = {2024},
  doi = {10.1007/s00011-024-01941-1}
}
Kostenlos starten →